摘要
目的 分析依诺肝素钠辅助拉贝洛尔治疗子痫前期的临床疗效。方法 研究对象为本院收治的100例子痫前期患者（收治时间范围：2023年1月~2024年1月）。所有子痫前期患者均自愿参与此次研究，并以简单随机法，将100例患者分为2组：对照组、观察组，50例/组。对照组-拉贝洛尔治疗；观察组-依诺肝素钠辅助拉贝洛尔治疗。对比2组子痫前期患者治疗前后临床指标、凝血功能指标、母婴结局。结果 治疗前，2组子痫前期患者的血压、心率指标比较：P＞0.05；治疗后，观察组子痫前期患者的血压、心率均达到正常水平，与对照组相比较（P＜0.05）；治疗前，2组子痫前期患者的凝血功能比较：P＞0.05；治疗后，观察组的凝血功能改善程度显著优于对照组，数据对比（P＜0.05）。观察组早产、产后出血、新生儿窒息发生率均低于对照组，差异性对比：P＜0.05。结论 对子痫前期患者采取依诺肝素钠辅助拉贝洛尔进行治疗，能够明显降低患者的血压，有效改善凝血功能，并减少不良妊娠结局发生，能够提升临床安全性，具有较高的作用价值。
关键词： 依诺肝素钠；拉贝洛尔；子痫前期；临床疗效
Abstract
Objective To analyze the clinical efficacy of enoxaparin sodium in the treatment of preeclampsia. Methods The study subjects were 100 preeclamptic patients admitted to our hospital (admission time range: January 2023 to January 2024). All preeclampsia patients volunteered to participate in the study and divided 100 patients into 2 groups: control group, observation group and 50 cases / group. Control group —— labeolol; observation group —— enoxaparin sodium adjuvant labeolol. Compared the clinical index, coagulation function index, and maternal and infant outcomes before and after treatment in group 2 of preeclamptic patients. Results Before treatment, blood pressure and heart rate comparison of preeclamptic patients: P> 0.05; after treatment, the preeclamptic patients reached normal levels, compared with the control group (P <0.05); before treatment, coagulation comparison of preeclamptic patients: P> 0.05; after treatment, the observation group improved significantly better than the control group, data comparison (P <0.05). The incidence of preterm birth, postpartum hemorrhage and neonatal asphyxia in the observation group were lower than that in the control group, and the difference was: P <0.05. Conclusion The treatment of enoxaparin sodium assisted alcohol in patients with preeclampsia can significantly reduce blood pressure, effectively improve coagulation function, reduce adverse pregnancy outcomes, improve clinical safety and has high effect value.
Key words： Enoxaparin sodium; Laelol; Preeclampsia; Clinical efficacy
参考文献 References
[1] 马红霞. 依诺肝素钠辅助拉贝洛尔对子痫前期的治疗效果分析[J]. 四川生理科学杂志,2023,45(9):1677-1678,1658.
[2] 王芳芳,王小莎,刘世东,等. 硝苯地平联合依诺肝素钠对重度子痫前期术后妊娠期高血压患者的应用效果[J]. 河北医药,2023,45(14):2165-2167,2171.
[3] Zhang, YiShen, FangrongYang, WeiwenWang, JuanZhou, JinhuaChen, Youguo.Effects of low-molecular-weight heparin and aspirin in recurrent pre-eclampsia: A stratified cohort study[J].International journal of gynecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2021, 154(2).
[4] 傅益萍,颜涛玲,黄睿. 钙剂联合低分子肝素钠治疗早发型重度子痫前期的有效性及安全性研究[J]. 四川生理科学杂志,2023,45(5):850-852.
[5] 郭君红. 低分子肝素钠联合硝苯地平及硫酸镁治疗重度子痫前期患者的疗效评价[J]. 黑龙江医药科学,2022,45(3): 49-50.
[6] 谭丽君. 硫酸镁注射液联合达肝素钠应用于重度子痫前期的临床观察[J]. 实用妇科内分泌电子杂志,2022,9(28): 73-75.
[7] 赖碧艳,陈嘉欣. 硝苯地平联合依诺肝素钠对重度子痫前期患者凝血功能及妊娠结局的影响[J]. 华夏医学,2022, 35(2):24-27.
[8] 俞海珍,廖志花,唐照青. 乌拉地尔联合低分子肝素钠对重度子痫前期患者凝血功能、血清ox-LDL水平的影响[J]. 实用中西医结合临床,2023,23(23):68-70,87.
[9] 许丽丽,王芳,文清,等. 依诺肝素钠与低分子肝素钠治疗重度子痫前期的疗效及对血清LPO、CysC和PIGF影响的对比研究[J]. 中国医院用药评价与分析,2021,21(8):925-928.
[10] 刘佳,董鹏,刘小玮,等. 运动-饮食综合干预联合硝苯地平和依诺肝素钠对重度子痫前期孕妇胎盘生长因子、同型半胱氨酸和血管内皮生长因子水平的影响[J]. 中国医学前沿杂志（电子版）,2021,13(8):54-58.
[11] 徐学娟,刘艳. 依诺肝素钠联合硫酸镁对早发型重度子痫前期患者PIGF、sFlt-1、vWF、p-选择素水平的影响[J]. 当代医学,2021,27(30):85-87.
[12] 焦艳艳. 依诺肝素钠联合硫酸镁治疗早发型重度子痫前期的临床疗效观察[J]. 现代诊断与治疗,2021,32(21):3388-3390.
[13] 曹美. 硫酸镁联合低分子肝素钠对重度子痫前期患者血压控制及母婴预后的影响[J]. 实用中西医结合临床,2021, 21 (18): 88-89.
[14] 卜春艳,范永周,王素影,等. 硫酸镁注射液联合低分子肝素钠治疗重度子痫前期疗效及对GSN、VDBP和凝血功能影响[J]. 中国计划生育学杂志,2019,27(11):1482-1485.
[15] 王盈红,钮慧远,郑晓晓,等. 小剂量阿司匹林联合拉贝洛尔治疗子痫前期的疗效研究[J]. 中国医院用药评价与分析,2023,23(2):208-211.